A landmark claims-based study of nearly 4,000 Mississippi Medicaid members found that about half of patients stopped using GLP-1 weight-loss drugs within months. The analysis linked steep adherence declines to younger age, Black race, and early-shortage initiation, according to the report. The findings underscore how real-world access and continuity challenges can undercut the intended benefits of modern anti-obesity pharmacotherapy, even after prescriptions are written. The study also points to potential equity implications tied to early discontinuation. For biotech and payers, the results highlight that reimbursement coverage and initial availability may not be enough; patient-level retention and supply-chain reliability may be decisive for outcomes at population scale.